Form 4: Akebia Therapeutics Director Michael W. Rogers Granted Significant Equity Awards

Akebia Therapeutics, Inc. Director Michael W. Rogers was granted 35,700 restricted stock units and options to purchase 53,600 shares of common stock as part of the company's non-employee director compensation program.

Summary

• Michael W. Rogers, a Director of Akebia Therapeutics, Inc. (AKBA), was granted equity awards on June 10, 2025.
• The awards include 35,700 Restricted Stock Units (RSUs) and stock options to purchase 53,600 shares of common stock.
• The RSUs were granted at a price of $0.00, and the stock options have an exercise price of $3.92 per share.
• Both the RSUs and stock options will vest in full (100%) on the first anniversary of the grant date, or earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, contingent on Mr. Rogers' continued service.
• Following these transactions, Mr. Rogers beneficially owns 161,729 shares of common stock directly and 53,600 derivative securities (stock options).
• The grants were made under the Issuer's 2023 Stock Incentive Plan and the Fourth Amended and Restated Non-Employee Director Compensation Program.

Sentiment

Score: 7

Explanation: The filing indicates standard and expected compensation practices for a director, aligning their interests with the company's long-term performance. It's a neutral to slightly positive signal regarding corporate governance and director retention.

Positives

• The equity grants align the director's incentives with shareholder interests, promoting long-term value creation.
• The awards are part of a standard, pre-established compensation program, indicating stable and transparent corporate governance practices.
• The grants serve as a mechanism for retaining key board members, ensuring continuity in leadership and strategic oversight.

Future Outlook

The vesting schedule for the granted RSUs and stock options indicates a future commitment of the director to the company, with full vesting expected on the first anniversary of the grant date, subject to continued service.

Industry Context

Equity grants to non-employee directors are a common practice across the biotechnology and pharmaceutical industries, serving to align the interests of board members with those of shareholders and to incentivize long-term commitment and performance. This filing reflects standard compensation practices for board members in publicly traded companies.

Comparison to Industry Standards

• The grant of RSUs and stock options to a non-employee director is a standard compensation mechanism in the biotech industry, comparable to practices at companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which often use a mix of cash and equity to compensate their board members.
• The vesting schedule (one year) is also typical for such grants, aiming to retain directors and align their long-term interests with company performance.
• The specific value and number of shares granted would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide such comparative data.

Corporate Governance

Related Party Transactions

• Grant of 35,700 Restricted Stock Units and options to purchase 53,600 shares of common stock to Michael W. Rogers, a Director of Akebia Therapeutics, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: Director's interests are further aligned with shareholders through equity ownership, potentially leading to better long-term decision-making.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of 35,700 Restricted Stock Units on June 10, 2026 (or earlier, prior to the first annual meeting after grant).
• Stock options for 53,600 shares become exercisable on June 10, 2026 (or earlier, prior to the first annual meeting after grant).

Key Dates

Recommendation

Keywords

Akebia Therapeutics, AKBA, SEC Form 4, Beneficial Ownership, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Director Compensation, Insider Transaction, Michael W. Rogers, 2023 Stock Incentive Plan